THE Magnifying LeNS LEARNING NEW SCIENCE QUARTERLY

OCTOBER 2021
GO2 in Action: Our Involvement in the 2021 World Conference on Lung Cancer

This month, our team virtually attended IASLC’s 2021 World Conference on Lung Cancer. Our science and research team provided strong representation for the organization and the lung cancer community through a combination of presentations, involvement as chairs and discussants, and contributions as co-authors on talks by international collaborators.

READ MORE
A New Look at Targeted Therapies for 2021 and Beyond

The World Conference on Lung Cancer highlighted many up-and-coming treatments for patients with different mutations, while also shedding light on proven existing drugs. Many talks at WCLC reinforced previously presented data for already approved targeted therapies. We have compiled an overview of the talks at WCLC which highlighted either ongoing trials or very newly approved drugs for common mutations in non-small cell lung cancer.
A Look at Immunotherapies from the World Conference on Lung Cancer

The 2021 World Conference on Lung Cancer saw several research presentations that helped increase our understanding of immunotherapy as a treatment for people with lung cancer and how we might better be able to use it to help more people. Here are some of the key takeaways of recent advancements in the immunotherapy space.
Treatments and Other Advances in Early-Stage Non-Small Cell Lung Cancer

The 2021 World Conference on Lung Cancer had multiple researchers presenting their findings on broad areas of research in early-stage lung cancer. These presentations bring highly encouraging news to the lung cancer community—an interest in understanding and establishing diagnostic and treatment methods for early stages, when the disease is more treatable.
Antibody Response to COVID-19 Vaccination in People with Lung Cancer

At the World Conference on Lung Cancer, Dr. Jorge Gomez, MD from Icahn School of Medicine at Mount Sinai, New York presented new data on how people with lung cancer respond to vaccination against the SARS-CoV-2 virus that causes COVID-19. The presentation was on behalf of a research consortium headed by Dr. Fred R Hirsch, MD, PhD and Dr. Adolfo Garcia-Sastre, PhD from Mount Sinai which also includes University of Texas Southwestern, University of Colorado, University of Maryland, Vanderbilt University, and GO2 Foundation. This work was funded by the National Cancer Institute’s SeroNet Initiative.
The World Conference on Lung Cancer features research on all types of thoracic cancers—and small cell lung cancer is no exception. There were many talks on new research advances in SCLC. While none of them featured an immediate change in how a person with SCLC would be treated, they highlighted the huge amount of work that is going on in small cell research today. There were a few major themes.
About Us

Founded by patients and survivors, GO2 Foundation for Lung Cancer transforms survivorship as the world’s leading organization dedicated to saving, extending, and improving the lives of those vulnerable, at risk, and diagnosed with lung cancer.

DONATE TODAY!